Neurogene (Neurogene) Beginning Cash Position : $148.72 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Neurogene Beginning Cash Position?

Neurogene's Beginning Cash Position for the quarter that ended in Mar. 2024 was $148.72 Mil.

Neurogene's quarterly Beginning Cash Position declined from Sep. 2023 ($59.05 Mil) to Dec. 2023 ($0.00 Mil) but then increased from Dec. 2023 ($0.00 Mil) to Mar. 2024 ($148.72 Mil).

Neurogene's annual Beginning Cash Position declined from Dec. 2021 ($84.25 Mil) to Dec. 2022 ($70.54 Mil) but then increased from Dec. 2022 ($70.54 Mil) to Dec. 2023 ($82.02 Mil).

Neurogene Beginning Cash Position Historical Data

The historical data trend for Neurogene's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurogene Beginning Cash Position Chart

Neurogene Annual Data

Trend

Dec21

Dec22

Dec23

Beginning Cash Position

84.25

70.54

82.02

Neurogene Quarterly Data
	Dec21	Jun22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Beginning Cash Position	Get a 7-Day Free Trial			82.02	68.54	59.05	-	148.72

Neurogene Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Neurogene Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Neurogene's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Neurogene (Neurogene) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neurogene Inc (NAS:NGNE) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

535 W 24th Street, 5th Floor, New York, NY, USA, 10011

Website

https://www.neurogene.com

Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today's complex devastating neurological diseases into treatable conditions.

Neurogene (Neurogene) Headlines

From GuruFocus

Neurogene Announces Business Update and 2024 Outlook

By Business Wire • 01-05-2024

Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million

By Business Wire • 12-19-2023